KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Supernus Pharmaceuticals (SUPN) Receivables - Net: 2011-2025

Historic Receivables - Net for Supernus Pharmaceuticals (SUPN) over the last 13 years, with Sep 2025 value amounting to $171.3 million.

  • Supernus Pharmaceuticals' Receivables - Net rose 17.77% to $171.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was $171.3 million, marking a year-over-year increase of 17.77%. This contributed to the annual value of $142.1 million for FY2024, which is 1.44% down from last year.
  • As of Q3 2025, Supernus Pharmaceuticals' Receivables - Net stood at $171.3 million, which was up 21.60% from $140.8 million recorded in Q2 2025.
  • Supernus Pharmaceuticals' 5-year Receivables - Net high stood at $171.3 million for Q3 2025, and its period low was $127.1 million during Q1 2021.
  • Over the past 3 years, Supernus Pharmaceuticals' median Receivables - Net value was $144.2 million (recorded in 2023), while the average stood at $146.5 million.
  • In the last 5 years, Supernus Pharmaceuticals' Receivables - Net increased by 22.75% in 2022 and then dropped by 13.61% in 2023.
  • Supernus Pharmaceuticals' Receivables - Net (Quarterly) stood at $148.9 million in 2021, then rose by 11.12% to $165.5 million in 2022, then dropped by 12.90% to $144.2 million in 2023, then dropped by 1.44% to $142.1 million in 2024, then rose by 17.77% to $171.3 million in 2025.
  • Its last three reported values are $171.3 million in Q3 2025, $140.8 million for Q2 2025, and $145.6 million during Q1 2025.